FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019779933> ?p ?o ?g. }

• W2019779933 endingPage "1819" @default.
• W2019779933 startingPage "1816" @default.
• W2019779933 abstract "Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells. Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent. Approximately 20% to 25% of patients will experience cytomegalovirus (CMV) reactivation. We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily. The study design planned to enroll 128 patients, but stopping rules for early termination were met. Forty patients were evaluable. Median age was 58 years (range, 25–83 years); median number of prior therapies was 2 (range, 0–10). Diagnoses included chronic lymphocytic leukemia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma (ATLL) (1), marginal zone leukemia (1), large granular lymphocyte leukemia (2), acute lymphoblastic leukemia (1), and T-cell lymphoma (2). Patients received various alemtuzumab-containing regimens, including single agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and rituximab (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (hyper-CVAD) (4). Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770." @default.
• W2019779933 created "2016-06-24" @default.
• W2019779933 creator A5000750846 @default.
• W2019779933 creator A5006104041 @default.
• W2019779933 creator A5006474362 @default.
• W2019779933 creator A5021287587 @default.
• W2019779933 creator A5024822266 @default.
• W2019779933 creator A5027575595 @default.
• W2019779933 creator A5057822243 @default.
• W2019779933 creator A5084379902 @default.
• W2019779933 creator A5089428686 @default.
• W2019779933 date "2008-02-15" @default.
• W2019779933 modified "2023-10-12" @default.
• W2019779933 title "Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy" @default.
• W2019779933 cites W1833241997 @default.
• W2019779933 cites W2010294468 @default.
• W2019779933 cites W2019274594 @default.
• W2019779933 cites W2049884015 @default.
• W2019779933 cites W2060881050 @default.
• W2019779933 cites W2073770511 @default.
• W2019779933 cites W2111403010 @default.
• W2019779933 cites W2130887949 @default.
• W2019779933 cites W2143749371 @default.
• W2019779933 cites W2169167811 @default.
• W2019779933 cites W3191665899 @default.
• W2019779933 cites W4248306224 @default.
• W2019779933 doi "https://doi.org/10.1182/blood-2007-03-080010" @default.
• W2019779933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18039954" @default.
• W2019779933 hasPublicationYear "2008" @default.
• W2019779933 type Work @default.
• W2019779933 sameAs 2019779933 @default.
• W2019779933 citedByCount "90" @default.
• W2019779933 countsByYear W20197799332012 @default.
• W2019779933 countsByYear W20197799332013 @default.
• W2019779933 countsByYear W20197799332014 @default.
• W2019779933 countsByYear W20197799332015 @default.
• W2019779933 countsByYear W20197799332016 @default.
• W2019779933 countsByYear W20197799332017 @default.
• W2019779933 countsByYear W20197799332018 @default.
• W2019779933 countsByYear W20197799332019 @default.
• W2019779933 countsByYear W20197799332020 @default.
• W2019779933 countsByYear W20197799332021 @default.
• W2019779933 countsByYear W20197799332022 @default.
• W2019779933 countsByYear W20197799332023 @default.
• W2019779933 crossrefType "journal-article" @default.
• W2019779933 hasAuthorship W2019779933A5000750846 @default.
• W2019779933 hasAuthorship W2019779933A5006104041 @default.
• W2019779933 hasAuthorship W2019779933A5006474362 @default.
• W2019779933 hasAuthorship W2019779933A5021287587 @default.
• W2019779933 hasAuthorship W2019779933A5024822266 @default.
• W2019779933 hasAuthorship W2019779933A5027575595 @default.
• W2019779933 hasAuthorship W2019779933A5057822243 @default.
• W2019779933 hasAuthorship W2019779933A5084379902 @default.
• W2019779933 hasAuthorship W2019779933A5089428686 @default.
• W2019779933 hasBestOaLocation W20197799331 @default.
• W2019779933 hasConcept C126322002 @default.
• W2019779933 hasConcept C141071460 @default.
• W2019779933 hasConcept C203014093 @default.
• W2019779933 hasConcept C2522874641 @default.
• W2019779933 hasConcept C2775952470 @default.
• W2019779933 hasConcept C2776317777 @default.
• W2019779933 hasConcept C2776694085 @default.
• W2019779933 hasConcept C2776755627 @default.
• W2019779933 hasConcept C2777965375 @default.
• W2019779933 hasConcept C2778461978 @default.
• W2019779933 hasConcept C2779015954 @default.
• W2019779933 hasConcept C2779263901 @default.
• W2019779933 hasConcept C2779338263 @default.
• W2019779933 hasConcept C2779429289 @default.
• W2019779933 hasConcept C2779820661 @default.
• W2019779933 hasConcept C2780653079 @default.
• W2019779933 hasConcept C2781413609 @default.
• W2019779933 hasConcept C2911091166 @default.
• W2019779933 hasConcept C71924100 @default.
• W2019779933 hasConcept C90924648 @default.
• W2019779933 hasConceptScore W2019779933C126322002 @default.
• W2019779933 hasConceptScore W2019779933C141071460 @default.
• W2019779933 hasConceptScore W2019779933C203014093 @default.
• W2019779933 hasConceptScore W2019779933C2522874641 @default.
• W2019779933 hasConceptScore W2019779933C2775952470 @default.
• W2019779933 hasConceptScore W2019779933C2776317777 @default.
• W2019779933 hasConceptScore W2019779933C2776694085 @default.
• W2019779933 hasConceptScore W2019779933C2776755627 @default.
• W2019779933 hasConceptScore W2019779933C2777965375 @default.
• W2019779933 hasConceptScore W2019779933C2778461978 @default.
• W2019779933 hasConceptScore W2019779933C2779015954 @default.
• W2019779933 hasConceptScore W2019779933C2779263901 @default.
• W2019779933 hasConceptScore W2019779933C2779338263 @default.
• W2019779933 hasConceptScore W2019779933C2779429289 @default.
• W2019779933 hasConceptScore W2019779933C2779820661 @default.
• W2019779933 hasConceptScore W2019779933C2780653079 @default.
• W2019779933 hasConceptScore W2019779933C2781413609 @default.
• W2019779933 hasConceptScore W2019779933C2911091166 @default.
• W2019779933 hasConceptScore W2019779933C71924100 @default.
• W2019779933 hasConceptScore W2019779933C90924648 @default.
• W2019779933 hasIssue "4" @default.
• W2019779933 hasLocation W20197799331 @default.
• W2019779933 hasOpenAccess W2019779933 @default.

• next